Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Earnings Results

Y-mAbs Therapeutics (NASDAQ:YMAB) posted its quarterly earnings data on Friday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), RTT News reports. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The firm had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. During the same period in the previous year, the company earned ($0.18) earnings per share. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Stock Down 0.5 %

YMAB stock traded down $0.07 during trading on Friday, hitting $15.48. 580,428 shares of the company’s stock traded hands, compared to its average volume of 330,577. The stock has a fifty day moving average price of $14.11 and a two-hundred day moving average price of $13.17. Y-mAbs Therapeutics has a 52 week low of $4.69 and a 52 week high of $20.90. The stock has a market capitalization of $689.94 million, a price-to-earnings ratio of -27.64 and a beta of 0.68.

Wall Street Analyst Weigh In

A number of brokerages recently commented on YMAB. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Canaccord Genuity Group restated a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Finally, Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $21.14.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now owns 67,681 shares of the company’s stock, valued at $877,822.57. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the sale, the insider now directly owns 67,681 shares in the company, valued at approximately $877,822.57. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 100,000 shares of company stock worth $1,338,100. 22.50% of the stock is currently owned by insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.